Advertisement

Topics

Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis

02:52 EDT 20 Jun 2017 | Cancer Networks

Patients with myelofibrosis resistant or intolerant to ruxolitinib may have an alternative treatment option with the JAK2-selective inhibitor fedratinib, according to the results of a phase II study.

Original Article: Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis

NEXT ARTICLE

More From BioPortfolio on "Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...